Literature DB >> 29563121

Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma.

Shunan Qi1,2, May Y Huang3, Yong Yang2, Heiko Schöder3, Sewit Teckie1, Ariela Noy4, Karen Chau1, Joachim Yahalom1.   

Abstract

The role of [18F]fluorodeoxyglucose (FDG) positron-emission tomography (PET) in mucosa-associated lymphoid tissue (MALT) of marginal zone lymphoma remains poorly defined. We correlated initial PET with pathology, clinical factors, and outcome. From January 2001 to July 2012, 173 MALT lymphoma patients with a biopsied lesion identified on PET within 90 days of tissue biopsy were analyzed. PET positivity and intensity of FDG uptake were correlated with clinical factors and patient outcome. Among 173 accrued cases, biopsied site was PET avid in 123 patients (71%); median standardized uptake value (SUV) was 6.0 (range: 0.7-28.0), and SUV >10.0 in 20 patients (16%). PET avidity varied by organ sites. PET positivity correlated with higher International Prognostic Index, but not with 5-year overall survival (OS; 96% vs 88%, PET negative vs positive, P = .229) or 5-year progression-free survival (67% vs 56%, P = .493). SUV was an independent prognostic factor of OS, and an increased SUV was associated with a decreasing 5-year OS. Patients who presented with SUV ≥10 had a higher rate of subsequent large cell transformation (20% vs 5%, P = .035) and inferior OS (78% vs 92%, P = .008). The exact role of FDG PET in the management of MALT lymphoma, beyond initial staging, remains to be defined.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29563121      PMCID: PMC5873233          DOI: 10.1182/bloodadvances.2017013698

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  35 in total

1.  Utility of FDG-PET scanning in lymphoma by WHO classification.

Authors:  Rebecca Elstrom; Liang Guan; Gary Baker; Khozaim Nakhoda; Jo-Anne Vergilio; Hongming Zhuang; Stephanie Pitsilos; Adam Bagg; Lisa Downs; Amit Mehrotra; Scott Kim; Abass Alavi; Stephen J Schuster
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

2.  18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation.

Authors:  Domenico Albano; Giovanni Bosio; Raffaele Giubbini; Francesco Bertagna
Journal:  Leuk Lymphoma       Date:  2017-03-07

Review 3.  The management of nongastric MALT lymphomas.

Authors:  Emanuele Zucca; Anastasios Stathis; Francesco Bertoni
Journal:  Oncology (Williston Park)       Date:  2014-01       Impact factor: 2.990

4.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

Review 5.  Positron emission tomographic scans in lymphoma: convention and controversy.

Authors:  Stephen M Ansell; James O Armitage
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

6.  Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma.

Authors:  Ludovic Le Dortz; Sophie De Guibert; Sahar Bayat; Anne Devillers; Roch Houot; Yan Rolland; Marc Cuggia; Florence Le Jeune; Haïfa Bahri; Marie-Luce Barge; Thierry Lamy; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-18       Impact factor: 9.236

7.  A MALT lymphoma prognostic index.

Authors:  Catherine Thieblemont; Luciano Cascione; Annarita Conconi; Barbara Kiesewetter; Markus Raderer; Gianluca Gaidano; Maurizio Martelli; Daniele Laszlo; Bertrand Coiffier; Armando Lopez Guillermo; Valter Torri; Franco Cavalli; Peter W Johnson; Emanuele Zucca
Journal:  Blood       Date:  2017-07-18       Impact factor: 22.113

8.  (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients.

Authors:  Michal Weiler-Sagie; Olga Bushelev; Ron Epelbaum; Eldad J Dann; Nissim Haim; Irit Avivi; Ayelet Ben-Barak; Yehudit Ben-Arie; Rachel Bar-Shalom; Ora Israel
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

9.  The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi.

Authors:  S Luminari; I Biasoli; L Arcaini; A Versari; C Rusconi; F Merli; M Spina; A J M Ferreri; P L Zinzani; A Gallamini; S Mastronardi; C Boccomini; G Gaidano; A M D'Arco; F Di Raimondo; A M Carella; A Santoro; P Musto; M Federico
Journal:  Ann Oncol       Date:  2013-04-12       Impact factor: 32.976

10.  FDG avidity and PET/CT patterns in primary gastric lymphoma.

Authors:  Lea Radan; Doron Fischer; Rachel Bar-Shalom; Eldad J Dann; Ron Epelbaum; Nissim Haim; Diana Gaitini; Ora Israel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-17       Impact factor: 9.236

View more
  10 in total

1.  Pre-Therapeutic Total Lesion Glycolysis on [18F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy.

Authors:  Marius E Mayerhoefer; Anton Staudenherz; Barbara Kiesewetter; Michael Weber; Ingrid Simonitsch-Klupp; Peter Gibbs; Werner Dolak; Julius Lukas; Markus Raderer
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

2.  Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients.

Authors:  Khaled Elsayad; Gabriele Reinartz; Michael Oertel; Stephan Rehn; Jens Eismann; Sergiu Scobioala; Hendrik Berssenbrügge; Nicole Eter; Carsten Weishaupt; Hartmut H Schmidt; Birte Friedrichs; Inga Grünewald; Wolfgang Hartmann; Georg Lenz; Eva Wardelmann; Normann Willich; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2019-11-15       Impact factor: 3.621

3.  Different CT imaging findings between histological subtypes in patients with primary thyroid lymphoma.

Authors:  Tomohiro Ando; Hiroki Kato; Masayuki Matsuo
Journal:  Radiol Med       Date:  2022-01-15       Impact factor: 3.469

4.  The role of 18F-FDG PET/CT in diagnosis and treatment evaluation for ocular adnexal mucosa-associated lymphoid tissue lymphoma.

Authors:  Weifang Wang; Xiaochen Ni; Tianci Tang; Jie Wang; Yi Li; Xinmao Song
Journal:  Br J Radiol       Date:  2021-12-17       Impact factor: 3.039

5.  The use of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography integrated with computed tomography for accurate staging and surveillance in the case of mucosa-associated lymphoid tissue.

Authors:  Shunqing Zhang; Allen Rossetti-Chung; Sumit Sood; Stephanie Terezakis
Journal:  J Radiol Case Rep       Date:  2021-03-31

Review 6.  Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers.

Authors:  Vetri Sudar Jayaprakasam; Viktoriya Paroder; Heiko Schöder
Journal:  Semin Nucl Med       Date:  2021-05-06       Impact factor: 4.802

Review 7.  MRI and PET/MRI in hematologic malignancies.

Authors:  Marius E Mayerhoefer; Stephen J Archibald; Christina Messiou; Anton Staudenherz; Dominik Berzaczy; Heiko Schöder
Journal:  J Magn Reson Imaging       Date:  2019-07-01       Impact factor: 4.813

8.  Is There a Role for [18F]FDG PET-CT in Staging MALT Lymphoma?

Authors:  Dan Cohen; Chava Perry; Shir Hazut-Krauthammer; Mikhail Kesler; Yair Herishanu; Efrat Luttwak; Einat Even-Sapir; Irit Avivi
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

9.  18F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report.

Authors:  Yixuan Ren; Lele Huang; Yuping Han; Zhencun Cui; Jicheng Li; Chi Dong; Jiangyan Liu
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

10.  A spectrum of Thymic mucosa-associated lymphoid tissue lymphoma and Thymic amyloidosis in the patient with Auto immune disease: a case series.

Authors:  Hiromasa Arai; Michihiko Tajiri; Noritake Kikunishi; Sho Nakamura; Kenji Inafuku; Yoshihiro Ishikawa; Satoshi Ikeda; Akimasa Sekine; Koji Okudela; Tae Iwasawa; Munetaka Masuda
Journal:  Mediastinum       Date:  2021-06-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.